Patients with advanced lung cancer live longer when given immunochemotherapy before 3pm, a new study shows. The research led by Hunan Cancer Hospital and backed by the Chinese University of Hong Kong found that earlier treatment almost doubled the time patients went without disease worsening, known as progression-free survival. It also raised median overall survival by nearly 70%. Professor Tony Mok Shu-kam, chairman of clinical oncology at Chinese University and co-corresponding author, said on Friday, "The findings are highly encouraging as a simple adjustment to the timing of treatment may enhance therapeutic efficacy and improve survival at no additional cost to the patient or healthcare system." This is the first randomized study showing the impact of morning versus afternoon immunochemotherapy infusions. It opens new doors for optimizing lung cancer treatment schedules to save more lives.